The difference between state procurement and centralized procurement of medicines is as follows:
1, the purchaser is not the same
State procurement refers to the centralized procurement of medicines organized by the state. Multiple medical institutions through the centralized bidding and purchasing organization of drugs, in the form of bidding to buy the required drugs procurement method. The purpose of centralized bidding and purchasing of medicines is to ensure the smooth implementation of the basic medical insurance system for urban workers, to control the unethical practices in the purchase and sale of medicines at source, to standardize the purchase and sale of medicines in medical institutions, and to reduce the burden of medical expenses on society.
Collective procurement, on the other hand, refers to private procurement.
2, the sale price is not the same
State procurement through the centralized bidding and purchasing of medicines, the introduction of the market competition mechanism, to reduce the inflated prices of medicines.2021 February 3, 2021, the fourth batch of state-organized centralized purchasing of medicines in Shanghai opened the bidding, and produces the results of the proposed successful selection. The procurement produced 118 proposed winning enterprises, 158 proposed winning products, and the average price reduction of the proposed winning products was 52%.
Collected drugs will be sold at a more expensive price than nationally procured ones, and that's due to the lack of sales volume expected by companies, and the cost of purchasing them is generally higher than that of nationally procured ones.
3, the types of drugs are not the same
The centralized bidding and purchasing scope of the national procurement of medicines is generally for the clinical use of urban workers' basic medical services. Routine use and the use of large quantities of drugs must be centralized bidding and procurement of drugs.
There are more choices of drugs in centralized procurement. Many drugs for rare diseases are not included in the national procurement category. At this time, rare disease drugs have to be solved through centralized procurement.
The effect of the implementation of the centralized bidding and purchasing policy for drugs
On June 23, 2021, the fifth batch of centralized purchasing of state-organized medicines was opened in Shanghai, and the results of the proposed winners were produced. The centralized procurement*** 251 products of 148 enterprises were qualified to be selected, and the proportion of bidding products selected was 71%. In the fifth batch of centralized procurement of state-organized medicines, 11 products of 10 foreign-funded pharmaceutical enterprises were proposed to be selected, involving France's Sanofi, the U.S. General, Germany's Fresenius, and Israel's Teva, etc., and the number of foreign-funded enterprises selected was significantly higher than that in the previous four batches.
On June 28, 2021, the fifth batch of state-organized drug collection and selection results were officially announced, and 61 kinds of drugs were successfully procured. These collectively procured price reductions in both hypertension, coronary heart disease, diabetes and other common diseases, chronic disease drugs, as well as lung cancer, breast cancer, colorectal cancer and other major diseases drugs. In the fifth batch of national organization drug collection, injection varieties accounted for half of the total number of varieties collection, involving about 70% of the total amount of the collection, become the collection of "big".
The above content refers to Baidu Encyclopedia - centralized bidding and purchasing of drugs